Northway Biotech is proudly sponsoring the Emily Whitehead Foundation and the 2026 Believe Ball, supporting the organization’s mission to raise awareness, foster collaboration, and help expand access to life-changing therapies for patients worldwide.
The Emily Whitehead Foundation is dedicated to accelerating awareness, education, and access to innovative therapies for patients and their families. Inspired by Emily Whitehead’s pioneering CAR T-cell therapy journey, the Foundation brings together patients, caregivers, healthcare professionals, researchers, advocacy groups, and industry leaders to advance the future of treatment.
As the Foundation’s flagship fundraising event, the Believe Ball celebrates the progress made in cell and gene therapy while fostering collaboration across the broader healthcare and biopharmaceutical community. By sponsoring both the Emily Whitehead Foundation and the 2026 Believe Ball, Northway Biotech is proud to support efforts that help create new opportunities for patients in need of transformative treatments.
“Northway is proud to support the Emily Whitehead Foundation and the 2026 Believe Ball. With the opening of our new Cell Therapy CDMO, we are honored to join a community dedicated to turning scientific breakthroughs into new possibilities for patients and families,” says Prof. Vladas Algirdas Bumelis, Chief Executive Officer of Northway Biotech.
Expanding Cell Therapy Capabilities
The Sponsorship comes at an important moment for Northway Biotech as the company expands its advanced therapy offering through the launch of its new Cell Therapy CDMO. The facility strengthens Northway’s ability to support the development and manufacturing of cell-based therapies, complementing its established expertise across biologics and advanced therapeutics.
This investment reflects Northway’s long-term commitment to enabling the next generation of innovative treatments and supporting the organizations, researchers, and companies working to bring them to patients.
As Northway Biotech grows its presence in the advanced therapies sector, active engagement with the cell therapy community remains a key priority. Supporting foundations, advocacy organizations, and industry initiatives provides valuable opportunities to connect with stakeholders across the ecosystem, exchange knowledge, and contribute to the advancement of patient-focused innovation.
By partnering with organizations such as the Emily Whitehead Foundation, Northway Biotech aims to be an active participant in the global effort to accelerate the development and accessibility of transformative cell and gene therapies.
About Northway Biotech
Northway Biotech is a leading CDMO specializing in protein-based biologics and advanced therapies, offering comprehensive, end-to-end development and manufacturing services. With deep expertise in cell line development, process optimization, and cGMP manufacturing, the company supports programs from early development through to commercial production. Founded in 2004, the privately held company operates state-of-the-art facilities in Lithuania and the United States, supporting clients worldwide with tailored, cGMP-compliant solutions.
About the Emily Whitehead Foundation
The Emily Whitehead Foundation, a non-profit organization, is the leading voice of the patient for advanced therapies. Founded by the parents of Emily Whitehead, the first child to receive life-saving CAR T-cell therapy, the foundation advocates for greater access to advanced treatments and provides support to all individuals affected by cancer and rare disease. With a global network of scientists, industry collaborators, and generous contributors, the foundation is driven to turn Emily’s survivor story into countless more survivor stories. For more information, visit emilywhiteheadfoundation.org.